Suppr超能文献

乳腺癌耐药蛋白表达与可切除胰腺癌患者的早期复发和生存时间缩短相关。

Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.

机构信息

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Korea.

出版信息

Pathol Int. 2012 Mar;62(3):167-75. doi: 10.1111/j.1440-1827.2011.02772.x. Epub 2012 Feb 6.

Abstract

The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains dismal even after complete resection, with most recurrences occurring within 1-2 years postoperatively. Adenosine triphosphate (ATP)-binding cassette (ABC) transporters have been demonstrated to play major roles in multidrug resistance (MDR) of cancers. In this study, we evaluated the expression statuses and the clinical significance of MDR1 (ABCB1), MDR-associated proteins (MRPs/ABCC) 1, 2 and 3, and breast cancer resistance protein (BCRP/ABCG2) in 67 surgically resected PDACs by immunohistochemistry. MDR1, MRP1, MRP2, MRP3 and BCRP were expressed in 35 (52.2%), 56 (83.6%), 61 (91.0%), 49 (73.1%) and 49 (73.1%) out of 67 cases, respectively. The expression statuses of the MDR-related proteins were positively correlated with each other (P < 0.05). Tumors expressing MRP1 (P= 0.015), MRP2 (P= 0.022) and MRP3 (P < 0.001) demonstrated more frequent perineural invasion. MDR1 expression was significantly correlated with lymphatic invasion (P= 0.047). High BCRP expression in PDAC was a significant prognostic factor for early tumor recurrence (HR = 2.43, P= 0.003) and poor survival (HR = 2.63, P= 0.001). MDR-related proteins are frequently expressed in PDAC, and high BCRP expression is a significant independent predictor for early recurrence and poor survival. Immunohistochemical analysis for BCRP expression in PDAC may be a useful test in identifying a subgroup of patients with a poor prognosis.

摘要

胰腺导管腺癌(PDAC)即使在完全切除后预后仍然不佳,大多数复发发生在术后 1-2 年内。三磷酸腺苷(ATP)结合盒(ABC)转运蛋白已被证明在癌症的多药耐药(MDR)中起主要作用。在这项研究中,我们通过免疫组织化学方法评估了 67 例手术切除的 PDAC 中 MDR1(ABCB1)、MDR 相关蛋白(MRP/ABCC)1、2 和 3 以及乳腺癌耐药蛋白(BCRP/ABCG2)的表达状态及其临床意义。MDR1、MRP1、MRP2、MRP3 和 BCRP 在 67 例病例中的表达率分别为 35(52.2%)、56(83.6%)、61(91.0%)、49(73.1%)和 49(73.1%)。MDR 相关蛋白的表达状态彼此呈正相关(P < 0.05)。表达 MRP1(P=0.015)、MRP2(P=0.022)和 MRP3(P<0.001)的肿瘤更频繁地出现神经周围侵犯。MDR1 表达与淋巴血管侵犯显著相关(P=0.047)。PDAC 中高 BCRP 表达是肿瘤早期复发(HR=2.43,P=0.003)和生存不良(HR=2.63,P=0.001)的显著预后因素。MDR 相关蛋白在 PDAC 中频繁表达,BCRP 高表达是早期复发和不良生存的显著独立预测因子。PDAC 中 BCRP 表达的免疫组织化学分析可能是识别预后不良患者亚组的有用检测方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验